Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure

Circulation

Volumn 121, Issue 16, 2010, Pages 1818-1827

  Japp, A G ^a   Cruden, N L ^a   Barnes, G ^b   Van Gemeren, N ^a   Mathews, J ^a   Adamson, J ^c   Johnston, N R ^b   Denvir, M A ^a,b   Megson, I L ^c   Flapan, A D ^a   Newby, D E ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Apelin, AGTRL1 ligand, human; APJ receptor, human; Heart failure

Indexed keywords

ACETYLCHOLINE; APELIN; APELIN 13; APELIN 36; G PROTEIN COUPLED RECEPTOR; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; PLACEBO; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; FOREARM BLOOD FLOW; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMICS; HUMAN; IMPEDANCE CARDIOGRAPHY; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; CARDIAC OUTPUT; CHRONIC DISEASE; CORONARY CIRCULATION; FEMALE; FOREARM; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; NITROPRUSSIDE; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; VASODILATION; VASODILATOR AGENTS; VENTRICULAR PRESSURE;

EID: 77951768113     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.911339     Document Type: Article

References (32)

1. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355-360. (Pubitemid 24049270)
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-476. (Pubitemid 28505047)
3. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophys-iologic relevance and therapeutic potential. Biochem Pharmacol. 2008; 75:1882-1892.
4. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233-240. (Pubitemid 40128188)
5. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-440. (Pubitemid 35034212)
6. Salcedo A, Garijo J, Monge L, Fernandez N, Luis Garcia-Villalon A, Sanchez Turrion V, Cuervas-Mons V, Dieguez G. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept. 2007;144:50-55. (Pubitemid 350030302)
7. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65:73-82. (Pubitemid 40038480)
8. Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE, Joseph Woo Y. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007;12:127-138. (Pubitemid 46786647)
9. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92. (Pubitemid 32522535)
10. Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470:171-175. (Pubitemid 36694473)
11. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypo-tensive action. Endocrinology. 2005;146:231-236. (Pubitemid 40051744)
12. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Leibbrandt A, Makovic M, Schwaighofer J, Beetz N, Musialek R, Neely GG, Komnenovic V, Kolm U, Metzler B, Ricci R, Hara H, Meixner A, Nghiem M, Chen X, Dawood F, Wong KM, Sarao R, Cukerman E, Kimura A, Hein L, Thalhammer J, Liu PP, Penninger JM. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res. 2007;101:e32-e42. (Pubitemid 47267711)
13. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angio-tensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006; 41:798-806. (Pubitemid 44635562)
14. Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF. Apelin protects myocardial injury induced by isopro-terenol in rats. Regul Pept. 2006;133:147-154. (Pubitemid 41820348)
15. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mayranpaa M, Sarman B, Seres L, Skoumal R, Lako-Futo Z, deChatel R, Ruskoaho H, Toth M. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308:480-485. (Pubitemid 36945517)
16. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355-360.
17. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52: 908-913.
18. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97: 2222-2229. (Pubitemid 28265383)
19. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99:1411-1415. (Pubitemid 29140904)
20. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
21. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936-1941. (Pubitemid 32322219)
22. Thomas SH. Impedance cardiography using the Sramek-Bernstein method: accuracy and variability at rest and during exercise. Br J Clin Pharmacol. 1992;34:467-476.
23. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969;29:1349-1355.
24. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol. 2004;24:1043-1048. (Pubitemid 38737829)
25. Leslie SJ, Spratt JC, McKee SP, Strachan FE, Newby DE, Northridge DB, Denvir MA, Webb DJ. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart. 2005;91:914-919. (Pubitemid 40874081)
26. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol. 2001;52:631-646.
27. Negrao CE, Hamilton MA, Fonarow GC, Hage A, Moriguchi JD, Middlekauff HR. Impaired endothelium-mediated vasodilation is not the principal cause of vasoconstriction in heart failure. Am J Physiol. 2000; 278:H168-H174. (Pubitemid 30101868)
28. Chowienczyk PJ, Cockcroft JR, Ritter JM. Blood flow responses to intra-arterial acetylcholine in man: effects of basal flow and conduit vessel length. Clin Sci (Lond). 1994;87:45-51.
29. Schmitt M, Blackman DJ, Middleton GW, Cockcroft JR, Frenneaux MP. Assessment of venous capacitance: radionuclide plethysmography: methodology and research applications. Br J Clin Pharmacol. 2002;54: 565-576. (Pubitemid 36002582)
30. Larsen AI, Dickstein K, Ahmadi NS, Aarsland T, Kvaloy JT, Hall C. The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. Eur J Heart Fail. 2006;8:628-633. (Pubitemid 44572959)
31. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, Mayet J, Francis DP. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95:56-62.
32. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343-3354.